Enochian Biosciences Inc. is on track to file an IND application for its innovative cancer platform around the early part or middle of next year. If successful, that would allow clinical trials to begin in the first half of next year.
Monte Rosa Therapeutics Inc. has synthesized molecular glue degraders acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and cereblon (CRBN) interaction inducers for GSPT1 degradation reported to be useful for the treatment of cancer.
Cell cycle dysregulation in cancer cells represents a clinical option for treating cancer, by using cyclin-dependent kinase 4/6 (CDK4/6) inhibitory agents. Further evaluation on this approach was presented by TYK Medicines Inc., where they focused on the pharmacological action of a CDK7 inhibitor TY-2699a for the potential treatment of cancer.
Around 73,000 women are diagnosed with triple-negative breast cancer (TNBC) every year in the U.S. and EU. TNBC grows and spreads faster than other types of breast cancer; moreover, it has less treatment options, and usually, a worse prognosis.
Triple-negative breast cancer (TNBC) constitutes the most aggressive form of breast cancer and presents a high frequency of relapse. The available treatment options are limited and accompanied by resistance and significant treatment side effects.
Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a member of the cancer/testis antigens (CTAs) protein family, which is family of proteins that are mainly expressed in tumors and testicular tissue, but they display low to no expression in other normal tissues.
